Cdc7Mcm2在弥漫大B细胞淋巴瘤的表达与预后的相关性研究  

Cdc7 and Mcm2 Expression as Markers for the Proliferation and Prognosis of Diffuse Large B Cell Lymphoma

作　　者：王雅璇[1] 王华庆[1] 付凯[1] 侯芸[1] 张会来[1] 钱正子[1] 周世勇[1] 邱立华[1] 

机构地区：[1]天津医科大学附属肿瘤医院淋巴肿瘤科,中美淋巴血液肿瘤诊治中心,天津市肿瘤防治重点实验室,天津市300060

出　　处：《中国肿瘤临床》2011年第18期1088-1091,共4页Chinese Journal of Clinical Oncology

摘　　要：目的:探讨弥漫大B细胞淋巴瘤(DLBCL)患者中Cdc7、Mcm2的表达及与预后的关系。方法:收集2008年1月至2010年1月收治的60例DLBCL初治患者的性别、年龄、ECOG评分、Ann Arbor分期、IPI评分、骨髓累及、B症状有无、结外受累数目、血乳酸脱氢酶(LDH)数值、治疗模式、组织细胞来源等临床资料,应用免疫组化法测定组织蜡块中Cdc7、Mcm2蛋白的表达,分析其与预后的关系。结果:经单因素分析,Cdc7阳性和阴性表达者2年生存率分别为41%、73%(P<0.05);Mcm2阳性和阴性表达者分别为25%、75%(P<0.05);临床资料:ECOG评分(0～1分vs 2分)(76.7%vs 233%);Ann Arbor分期(Ⅰ～Ⅱ期vsⅢ～Ⅳ期)(65.0%vs 35.0%);IPI(0～1分vs≥2分)(78.3%vs 21.7%);LDH(正常vs高于正常)(70.0%vs 30.0%);单纯化疗vs化疗+放疗(41.7%vs 583%);GCB vs ABC来源(53.3%vs 46.7%)其2年生存率差异具有统计学意义(P<0.05)。Cdc7和Mcm2的表达与DLBCL的临床分期和IPI评分具有相关性(P<0.05),Ⅲ/Ⅳ期DLBCL患者Cdc7和Mcm2的表达高于Ⅰ/Ⅱ期患者,IPI评分越高,Cdc7和Mcm2的表达也越强。结论:除IPI评分、治疗模式、组织细胞来源是DLBCL的预后因素外,Cdc7和Mcm2高表达是影响DLBCL患者预后的不良因素。Objective： To assess the proliferative activity of diffuse large B cell lymphoma （ DLBCL ） using immunohistochemistry （ IHC ） and real-time polymerase chain reaction of Cdc7 and Mcm2 and to explore their potential value in predicting prognosis. Methods： From Jan 2008 to Jan 2010, the clinical characteristics of 60 DLBCL patients were collected using IHC to assess the expression of Cdc7 and Mcm2. A statistical analysis was conducted on the association of Cdc7 and Mcm2 with the clinicopathologic characteristics of DLBCLs. Results： In the univariate analysis, the 2-year overall survival rate of the patients with positive Cdc7 expression was 41%, and the patient with negative Cde7 expression was 73%, （ P 〈 0.05 ）. The 2-year overall survival rate of the patients with positive Mcm2 expression was 25%, and the patients with negative Mcm2 expression was 75% （ P 〈 0.05 ）. The clinical data were as follows： ECOG performance status （ 0-1 vs. 2 ） （ 76.6% vs. 23.4% ）; Ann Arbor stage （ Ⅰ-Ⅱ vs.Ⅲ-Ⅳ ） （ 65.0% vs. 35.0%）; IPI （ 0-1 vs. 1〉2 ） （ 78.3% vs. 21.7%）; LDH level （ normal vs. abnomaal ） （ 70.0% vs. 30.3%）; radiotherapy only vs. chemotherapy combined with radiotherapy （ 41.7% vs. 58.3% ）; and GCB subtype vs. non-GCB subtype （ 53.3% vs. 46.7% ）. ECOG performance status, Ann Arbor stage, International prognostic index （ IPI ）, LDH level, therapy model, and histological type were found to be the prognostic factors associated with the overall survival in DLBCL. The difference in 2-year overall survival rates between the different clinical indicators were significant. The patients with Cdc7- and Mcm2-positive DLBCL had a higher stage of disease than patients with Cdc7- and Mcm2-negative DLBCL. The patients with Cdc7- and Mem2-positive DLBCL had higher IPI of disease than patients with Cdc7- and Mcm2-negatire DLBCL. Conclusion： IP1, treatment, and different cell derivation were prognostic factors. Furthermore, poor disease specific survival is o

关 键 词：弥漫大B细胞淋巴瘤Cdc7 Mcm2预后因素 

分 类 号：R733.1[医药卫生—肿瘤]